With a better understanding of the molecular processes involved in Achondroplasia, various drug trials looking at blocking FGFR3 ligands, FGFR3 and its downstream signaling including tyrosine kinase inhibitors and C-type natriuretic peptide (CNP) analogs such as vosoritide, amongst others, are underway (22). The gene discussed is FGFR3; the disease is achondroplasia.